Genomictree Inc. (KOSDAQ:228760)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,010
-600 (-3.41%)
Aug 14, 2025, 3:30 PM KST
-3.41%
Market Cap408.32B
Revenue (ttm)2.39B
Net Income (ttm)-10.50B
Shares Out24.00M
EPS (ttm)-432.67
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume163,269
Average Volume157,625
Open17,520
Previous Close17,610
Day's Range16,900 - 17,520
52-Week Range11,390 - 24,500
Beta0.05
RSI64.81
Earnings DateAug 12, 2025

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 228760
Full Company Profile

Financial Performance

In 2024, Genomictree's revenue was 2.36 billion, a decrease of -30.89% compared to the previous year's 3.42 billion. Losses were -10.24 billion, 17.0% more than in 2023.

Financial Statements

News

There is no news available yet.